Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 2/20 | 0.48 |
| ▸ | HTR5A | P47898 | 1/20 | 0.46 |
| ▸ | AHR | P35869 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30293224 | 0.98 | SRD5A1 (0.55) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL22469447 | 0.89 | MAPT (0.53) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL261018 | 0.82 | AHR (0.61) | SRD5A1KIF11HTR5AAHRCA9 | |
| SCHEMBL30772369 | 0.81 | SRD5A1 (0.47) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL3593739 | 0.77 | NPC1 (0.50) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL1764695 | 0.77 | AHR (0.70) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL2230502 | 0.77 | NPC1 (0.50) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL29410901 | 0.77 | NPC1 (0.50) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL3593737 | 0.77 | NPC1 (0.50) | SRD5A1NPC1MAPK13MAPK12MAPK11 | |
| SCHEMBL6090116 | 0.77 | NPC1 (0.50) | SRD5A1NPC1MAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3768675-B1 | NOVEL TRIAZOLONE DERIVATIVES OR SALTS THEREOF AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | YUHAN CORP (KR) | 2026-04-01 | — | — | EP | claimed |
| EP-4561561-A2 | SUBSTITUTED 3,4-DIHYDROQUINOLINONE INHIBITORS OF TSHR | Septerna, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-3653618-B1 | NEW DIHYDROQUINOLINE-2-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-01-08 | — | — | EP | disclosed |
| US-20240343709-A1 | SUBSTITUTED HETEROCYCLES AS ALDEHYDE DEHYDROGENASE INHIBITORS | THE TRUSTEES OF PRINCETON UNIVERSITY | 2024-10-17 | — | — | US | disclosed |
| CN-116102537-B | Quinolinone derivative and preparation method and application thereof | 四川大学 | 2024-10-01 | — | — | CN | disclosed |
| US-12054475-B2 | Substituted heterocycles as aldehyde dehydrogenase inhibitors | KAYOTHERA INC. (US) | 2024-08-06 | — | — | US | disclosed |
| US-20240208953-A1 | \"Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B\ | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2024-06-27 | — | — | US | disclosed |
| US-20240132469-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | KAYOTHERA INC. (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117897370-A | Heterocyclic compounds and their use | 凯悦施那有限公司 | 2024-04-16 | — | — | CN | disclosed |
| EP-4326696-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Kayothera Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| US-7141588-B2 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PFIZER, INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1478629-B1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN CO LLC (US) | 2006-10-11 | — | — | EP | disclosed |
| US-6919329-B2 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-07-19 | — | — | US | disclosed |
| EP-1478629-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATIVES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-24 | — | — | EP | disclosed |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-29 | — | — | US | disclosed |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | PHARMACIA & UPJOHN COMPANY | 2004-03-04 | — | — | US | disclosed |
| WO-2003072553-A1 | N-ARYL-2-OXAZOLIDINONE-5-CARBOXAMIDES AND THEIR DERIVATES AND THEIR USE AS ANTIBACTERIALS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
| EP-0551927-A1 | Method for the treatment of cardiac insufficiency | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-07-21 | — | — | EP | disclosed |
| EP-0524846-A1 | 2-(Piperidin-1-yl)ethanol derivatives, their preparation and their use in therapeutics | SYNTHELABO (FR) | 1993-01-27 | — | — | EP | disclosed |
| EP-0219782-A2 | Use of angiotensin-converting enzyme inhibitors in the treatment of atherosclerosis, thrombosis and peripheral vascular disease | HOECHST AKTIENGESELLSCHAFT (DE) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343709-A1 | SUBSTITUTED HETEROCYCLES AS ALDEHYDE DEHYDROGENASE INHIBITORS | ALDH3A1, ALDH2, ALDH1A2 | SRD5A1 72/4885NPC1 2715/4885MAPK13 1899/4885 |
| US-12054475-B2 | Substituted heterocycles as aldehyde dehydrogenase inhibitors | ALDH3A1, ALDH2, ALDH1A2 | SRD5A1 72/4885NPC1 2715/4885MAPK13 1899/4885 |
| US-20240208953-A1 | \"Cyclopenta[c]pyrrol Negative Allosteric Modulators of NR2B\ | GRIN2C, GRIN2B, GRIN2A | SRD5A1 2141/4885NPC1 2885/4885MAPK13 1097/4885 |
| US-20040147760-A1 | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | SRD5A1 2478/4885NPC1 2741/4885MAPK13 2775/4885 |
| US-20040044052-A1 | N-Aryl-2-oxazolidinone-5-carboxamides and their derivatives | OXA1L, AADAC, MT-ND5 | SRD5A1 2478/4885NPC1 2741/4885MAPK13 2775/4885 |
| US-20240132469-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | CYP11B2, ALDH2, PDK1 | SRD5A1 67/4885NPC1 2082/4885MAPK13 1262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.